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Abstract
Despite the proven success of hormonal therapy for prostate cancer using chemical or surgical castration, most
patients eventually will progress to a phase of the disease that is metastatic and shows resistance to further
hormonal manipulation. This has been termed metastatic castrate-resistant prostate cancer (mCRPC). Despite this
designation, however, there is evidence that androgen receptor (AR)-mediated signaling and gene expression can
persist in mCRPC, even in the face of castrate levels of androgen. This may be due in part to the upregulation of
enzymes involved in androgen synthesis, the overexpression of AR, or the emergence of mutant ARs with
promiscuous recognition of various steroidal ligands. The therapeutic options were limited and palliative in nature
until trials in 2004 demonstrated that docetaxel chemotherapy could significantly improve survival. These results
established first-line docetaxel as the standard of care for mCRPC. After resistance to further docetaxel therapy
develops, treatment options were once again limited. Recently reported results from phase 3 trials have shown
that additional therapy with the novel taxane cabazitaxel (with prednisone), or treatment with the antiandrogen
abiraterone (with prednisone) could improve survival for patients with mCRPC following docetaxel therapy.
Compared with mitoxantrone/prednisone, cabazitaxel/prednisone significantly improved overall survival, with a 30%
reduction in rate of death, in patients with progression of mCRPC after docetaxel therapy in the TROPIC trial.
Similarly, abiraterone acetate (an inhibitor of androgen biosynthesis) plus prednisone significantly decreased the
rate of death by 35% compared with placebo plus prednisone in mCRPC patients progressing after prior docetaxel
therapy in the COU-AA-301 trial. Results of these trials have thus established two additional treatment options for
mCRPC patients in the “post-docetaxel space.” In view of the continued AR-mediated signaling on mCRPC, results
from additional phase 3 studies with novel antiandrogens which are directed at inhibition of the AR (e.g.,
MDV3100), as well as other agents, are awaited with interest and may further expand the treatment choices for this
difficult-to-manage population of patients.
Introduction
Prostate cancer is the most frequently diagnosed non-
skin cancer, and the second leading cause of cancer
death, in men residing in the United States [1]. It is well
understood that the initial growth of prostate cancer is
dependent on androgens; therefore, hormonal therapy
remains a first-line treatment [2-4]. Initial responses to
hormonal therapy with chemic a lo rs u r g i c a lc a s t r a t i o n
are quite favorable, with rapid biochemical responses, as
assessed by declines in levels of the serum marker,
prostate-specific antigen (PSA) [3,5,6]. However, most
patients showing an initial response to hormonal therapy
for prostate cancer will progress to a castration-insensi-
tive phase of the disease which carries a much poorer
prognosis [3,4,6]. Treatment of patients with metastatic
castrate-resistant prostate cancer (mCRPC) remains a
significant clinical challenge.
In 2004, the results of two major phase 3 clinical trials
established docetaxel as a primary chemotherapeutic
option for patients with mCRPC [7,8]. Additional hormo-
nal treatment with antiandrogens, chemotherapy, combina-
tion therapies, and immunotherapy, has been investigated
for mCRPC, and recent results have offered additional
options in this difficult-to-treat patient group [9,10].
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treated with chemotherapy were reported as less than 1
year [11]; more recently, survival times of approximately
22 months have been observed [12]. In this review, we
examine treatment options for mCRPC, particularly for
men who progress following treatment with first-line
chemotherapy with docetaxel/prednisone, the current
standard of care.
Molecular aspects of CRPC
Evidence for persistent androgen dependence
Studies have suggested, even in the presence of castrate
levels of androgen, androgen levels in the prostate of
men with CRPC still remain nearly equivalent of those
in non-castrate patients [13]. The source of these andro-
gens is thought to be derived from synthesis of the
androgens directly in prostate cancer cells due to an
upregulation of the enzymes necessary to synthesize
androgens such as testosterone and dihydrotestosterone
[14,15]. These findings suggest that prostate cancer that
recurs despite castrate serum testosterone levels is not
truly androgen-independent.
Several other mechanisms also may result in activation
of the AR in prostate cancer in the face of castrate levels
of androgen. These include increased AR expression
through gene amplification and other mechanisms [16],
mutations of the AR that can affect its ligand promiscu-
ity, and molecular cross-talk with other signaling path-
ways and co-regulators that lie downstream of the AR
[2,5,17].
Studies from Hu et al. [18] have shown that splice var-
iants of the AR may be identified that encode ligand-
domain deleted proteins that are constitutively activated
and more abundantly expressed in CRPC than in hor-
mone-naïve disease. Studies from Sun et al. [19] also have
identified splice variants of the AR that are truncated and
constitutively activated. Recent data from Watson et al.
[20] suggest that expression of splice variants of the AR in
CRPC actually could be dependent on hormonal therapy,
such that these variants are expressed within days of cas-
tration, and diminish after androgen treatment. These
androgen-independent variants of the AR are sufficient to
confer castration-resistant growth to prostate cancer cells.
Interestingly, however, in model systems they may be
inhibited by antiandrogens targeted to the ligand-binding
domain, such as MDV3100 (see below) [20]. Hypotheti-
cally this may be a consequence of inhibiting wild-type
ARs, which form heterodimers with truncated splice
variant ARs.
Multiple pathways may be amenable to therapeutic
intervention for patients with CRPC. In view of the per-
sistence of both AR and tissue androgens in recurrent
prostate cancer, therapies that directly target the AR, or
affect the persistence of androgens in prostate tissue,
m a yb eo fv a l u ef o rp a t i e n t sw i t hC R P C[ 1 3 , 2 0 ] .H o w -
ever, additional therapeutic strategies, including che-
motherapy and immunotherapy, also have demonstrated
benefit in CRPC, particularly in terms of the most
important outcome of improved survival.
Treatment options - then and now
Prior to 2004, there was no treatment proven to improve
survival for men with mCRPC. The treatment of patients
with mitoxantrone with prednisone or hydrocortisone
was aimed only at alleviating pain and improving quality
of life, but there was no benefit in terms of overall survi-
val (OS) [11,21]. In 2004, however, two key trials, TAX
327 and SWOG (Southwest Oncology Group) 9916,
demonstrated a benefit for docetaxel-based regimens in
the treatment of men with CRPC [7]. In TAX 327, a 24%
relative reduction in death for men with mCRPC was
observed with a 3-weekly docetaxel with prednisone regi-
men (hazard ratio [HR] for death = 0.76; 95% confidence
interval [CI] = 0.62-0.94), and the benefit in survival rate
compared with patients receiving mitoxantrone and pre-
dnisone was significant (P = 0.009) [7]. Docetaxel also
was effective in providing palliative relief, with 35% of
patients reporting reduction in pain vs 22% with mitox-
antrone (P = 0.01) [7]. Outcomes of TAX 327 demon-
strated that chemotherapy with docetaxel was a viable
option that prolonged survival for patients with mCRPC
[7]; moreover, with an extended follow-up, the survival
benefit of docetaxel in the TAX 327 trial has persisted
[22]. In SWOG 9916, a regimen of docetaxel + estramus-
tine was compared with mitoxantrone and prednisone
[8]. In this study, the docetaxel regimen also conferred a
significant survival benefit over the comparator (HR for
death = 0.80; 95% CI = 0.67-0.97), and increased median
survival (17.5 vs 15.6 months; P = 0.02) [8]. At present,
docetaxel/prednisone remains the first-line chemother-
apy of choice for patients with CRPC.
Docetaxel combinations
Combinations of docetaxel and different drug classes,
including tyrosine kinase inhibitors, antiangiogenesis
agents, and immunologic agents, have been evaluated in
phase 2 studies for CRPC [23]. Whereas trials of some
combinations, such as GVAX and DN-101, have termi-
nated early due to increased toxicity and poorer survival,
combination trials with other agents, including afliber-
cept and dasatinib, are under way [23,24]. A phase 2
study (N = 60) of docetaxel, bevacizumab, thalidomide,
and prednisone found 50% or greater PSA declines in
90% of patients with mCRPC and a median overall survi-
val of 28.2 months. Toxicity of the regimen was manage-
able but, notably, virtually all patients developed grade 3
or 4 neutropenia [25]. Addition of bevacizumab to doce-
taxel did not prolong survival in a recently reported
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therapy with docetaxel has not produced any viable ther-
apeutic options. Relevant phase 3 trials under way in this
area include combination of docetaxel with antiangiogen-
esis agents such as aflibercept, bone-seeking radioiso-
topes such as strontium-89, inhibitors of endothelin
receptors such as zibotentan (ZD4054; see below), and
signal transduction/kinase inhibitors such as dasatinib.
The post-docetaxel space
Although docetaxel produces a modest survival benefit
in patients, the therapy is not curative and some
patients will require treatment with additional therapies.
Such is the nature of the current “post-docetaxel space,”
which, until recently, was devoid of a viable treatment
option for CRPC patients following progression post-
docetaxel. A number of treatment modalities have been
proposed; those with most promising trial results, out-
lined in further detail below. Docetaxel retreatment has
been advocated by some investigators [26], but given
recent advances with newer medications, it is likely this
approach will be used less often in the future. In addi-
tion, ketoconazole has substantial activity in prostate
cancer both pre- and post-docetaxel [27,28]. It should
also be mentioned that sunitinib, despite phase 2 sup-
portive data [29], recently failed in a phase 3 trial.
Cytotoxic agents
Satraplatin - SPARC trial
In the phase 3 SPARC trial, satraplatin, a third-genera-
tion, platinum-based chemotherapy, was used with pre-
dnisone in patients with CRPC who progressed through
at least one prior chemotherapy (N = 950) [24,30].
Results for the co-primary endpoint of progression-free
s u r v i v a l( P F S )s h o w e dt h a ts a t r a p l a t i nr e d u c e dr i s kf o r
progression or death by 33% compared with placebo (HR
= 0.67; 95% CI = 0.57-0.77; P < 0.001). OS, however, was
not significantly different between the groups (HR = 0.98;
95% CI = 0.84-1.15; P = 0.80) [30]. The drug was gener-
ally well tolerated; key adverse events (AEs) were myelo-
suppression and gastrointestinal disorders, which were
more frequent with satraplatin.
Cabazitaxel - TROPIC
Cabazitaxel [10] is a novel taxane-class cytotoxic agent
[31] that has shown efficacy in model system tumors that
are resistant to paclitaxel and docetaxel [32,33]. In a
recently published, randomized, multicenter, phase 3
trial, the efficacy and safety of cabazitaxel and prednisone
were compared with those of mitoxantrone and predni-
sone for the treatment of mCRPC that had progressed
following docetaxel-based chemotherapy [10]. A total of
755 patients were randomly assigned to treatment with
cabazitaxel (N = 378) or mitoxantrone (N = 377), and the
median follow-up for both treatment groups was 12.8
months [10]. Kaplan-Meier analysis demonstrated a sig-
nificant benefit in OS for patients assigned to cabazitaxel,
with a significant (P < 0.0001) 30% reduction in death
(HR = 0.70; Table 1); the median OS was 15.1 months
with cabazitaxel, compared with 12.7 months with mitox-
antrone. The composite endpoint of median PFS (defined
as the time between randomization and first date of PSA
progression, tumor progression, pain progression, or
death) also favored the cabazitaxel arm (2.8 vs 1.4
months; P < 0.0001). Tumor response (14.4% vs 4.4%;
P = 0.0005) and PSA response (39.2% vs 17.8%; P =
0.0002) also significantly favored cabazitaxel, as did med-
ian time to tumor progression (8.8 vs 5.4 months; P <
0.0001) and median time to PSA progression (6.4 vs 3.1
months; P = 0.001). Pain response and time to pain pro-
gression were similar between the treatment groups [10].
Hematologic toxicities (neutropenia, leukopenia, anemia)
were the predominant grade 3 or higher AEs associated
with cabazitaxel in the study; the most common clinical
grade 3 or higher AEs were febrile neutropenia and diar-
rhea. Grade 3 neuropathy was uncommon (1% for cabazi-
taxel). The findings of TROPIC established cabazitaxel as
the first agent to prolong survival in the post-docetaxel
space, with a 30% reduction in death over mitoxantrone
[10]. On the basis of these data, cabazitaxel has been
approved by the US Food and Drug Administration for
use in patients with mCRPC who have progressed after
docetaxel [34]. Results of subgroup analysis in TROPIC
also should be mentioned, as these showed a benefit of
cabazitaxel over mitoxantrone in patients progressing
during docetaxel treatment and in those receiving more
prolonged dosing with docetaxel [10]. In the TROPIC
trial, the median time from last docetaxel dose to pro-
gression was less than one month; also, these patients
were heavily pretreated with a median of 7 cycles of doc-
etaxel pre-TROPIC enrollment. Still, it should be noted
that cabazitaxel can be associated with substantial toxi-
city, and deaths within 30 days of the last dose were
reported in 4.9% of patients. This toxicity was primarily
related to myelosuppression, but diarrhea could also be
severe. First cycle monitoring with weekly CBC is recom-
mended and primary prophylaxis with G-CSF is recom-
mended for men over the age 65 and for those with a
poor performance status, previous episodes of febrile
neutropenia, extensive prior radiation ports, poor nutri-
tional status, or other serious comorbidities [35].
Abiraterone Acetate - COU-AA-301
Antiandrogen therapy is designed to further inhibit andro-
gen-mediated signaling, which may be mediated by resi-
dual adrenal androgen in pros t a t et i s s u e[ 4 ] .I n t e r i m
analysis of the COU-AA-301 trial was recently reported at
the 2010 European Society for Medical Oncology Con-
gress [9]. In this trial, the safety and efficacy of abiraterone
acetate (AA) with prednisone was compared with that of
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treated with docetaxel, with the primary endpoint of OS.
AA is an orally administered pregnenolone analog, which
further reduces androgen levels in CRPC via the inhibition
of CYP17, a rate-limiting enzyme in androgen biosynthesis
[36]. This drug has been shown to have activity in mCRPC
with acceptable toxicity in phase 1 studies [37]. Principle
side effects associated with this agent include hyperten-
sion, hypokalemia, and edema, which appear to be man-
ageable with mineralocorticoid antagonists or low-dose
corticosteroids [36,38]. In COU-AA-301, both fluid reten-
tion (30.5% vs 22.3%) and hypokalemia (17.1% vs 8.4%)
were more common with AA compared with placebo,
whereas grade 3 and 4 hypokalemia (3.8% vs 0.8%) and
hypertension (1.3% vs 0.3%) were observed infrequently
[9]. The efficacy findings of the trial (Table 1) prompted
the Independent Data Monitoring Committee to recom-
mend unblinding the trial at the time of the interim analy-
sis and the crossover of patients from the placebo arm to
AA. These results showed a significant improvement in
OS, time to PSA progression, radiographic PFS, and PSA
response for patients treated with AA, relative to those on
placebo (Table 1) [9]. The results of COU-AA-301 con-
firm that targeting persistent androgen biosynthesis is a
viable therapeutic option for men with progressive disease
despite medical or surgical castration. A new drug applica-
tion (NDA) was filed with the US regulatory authorities in
December 2010, with abiraterone/prednisone currently
being evaluated in a phase 3 trial in metastatic, che-
motherapy-naïve CRPC patients.
MDV3100
As noted earlier, therapies that effectively and directly
block AR activity, as opposed to suppressing residual
androgen levels, may be of therapeutic value in CRPC.
MDV3100 is an AR antagonist that blocks androgen bind-
ing and prevents nuclear translocation and recruitment of
coactivators [24,39]; it has been shown to confer a tumor
response in men with CRPC after failure of prior hormonal
therapy, with 43% showing a ≥50% PSA response in a
p h a s e1 / 2s t u d y[ 4 0 , 4 1 ] .I na n o t h e rp h a s e1 / 2s t u d yo fm e n
with CRPC without metastases, MDV3100 demonstrated
antitumor activity in men both with and without prior che-
motherapy exposure, validating the importance of contin-
ued AR signaling in tumor growth for men with CRPC
[39]. As noted earlier, AR splice variants lacking the
ligand-binding domain have been identified, and these
were predicted to play an important role in the develop-
ment of castration resistance in prostate cancer; surpris-
ingly, the cells expressing these variants were found to be
inhibited by MDV3100 despite the absence of a ligand-
binding domain in some ARs [20]. These findings suggest
that MDV3100 could partly prevent some of the androgen
independence conferred by these variants in prostate can-
cer patients. Currently, there are two phase 3 clinical trials
under way with MDV3100 for men with CRPC, one of
which will examine safety and efficacy in men with meta-
static chemotherapy-naïve disease (ClinicalTrials.Gov:
NCT01212991), and another (ClinicalTrials.Gov: NCT00
974311) examining safety and efficacy of MDV3100 in
men post docetaxel therapy [39]. The post-docetaxel ther-
apy trial recently completed accrual. Newer agents
designed to block CYP17 activity such as TAK-700 are also
now in phase 3 trials both pre- and post-docetaxel in meta-
static CRPC. In addition, ARN-509 is a new and potent
antiandrogen in clinical development.
Vaccine immunotherapy
Sipuleucel-T
Sipuleucel-T is a vaccine-type immunotherapy designed
to stimulate an immune response to prostate cancer
cells [42]. In a small (N = 127), placebo-controlled,
phase 3 study (N = 82 sipuleucel-T, N = 45 placebo),
Table 1 Currently proven treatment options for mCRPC patients in the post-docetaxel space [9,10]
Drug (trial) Class (comparator) Primary outcomes vs comparator (hazard
ratio [HR])
95% CIs P value
Abiraterone acetate + prednisone
(COU-AA-301)
Antiandrogen
(prednisone/placebo)
Median OS = 14.8 vs 10.9 mo
(HR = 0.65)
0.54-0.77 < 0.0001
Median TTPP = 10.2 vs 6.6 mo
(HR = 0.58)
0.46-0.73 < 0.0001
Median rPFS = 5.6 vs 3.6 mo
(HR = 0.67)
0.58-0.78 < 0.0001
PSA response: 38% vs 10% - < 0.0001
Cabazitaxel + prednisone (TROPIC) Chemotherapy (mitoxantrone/
pred-nisone)
Median OS = 15.1 vs 12.7 mo
(HR = 0.70)
0.59-0.83 < 0.0001
Median PFS = 2.8 vs 1.4 mo
(HR = 0.74)
0.64-0.86 < 0.0001
Tumor response = 14.4% vs 4.4% - 0.0005
PSA response = 39.2% vs 17.8% - 0.0002
CIs: confidence intervals; mCRPC: metastatic castrate-resistant prostate cancer; mo: months; OS: overall survival; PFS: progression-free survival; PSA: prostate-
specific antigen; rPFS: radiologic PFS; TTPP: time to pain progression.
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benefit in survival for men with mCRPC, and the treat-
ment was generally well tolerated (prior chemotherapy
was permitted if at least 6 months had elapsed, or 3
months, if the CD4+ cell count was > 400) [42,43].
These findings formed the basis for the IMPACT trial,
which examined the efficacy and safety of sipuleucel-T
(N = 341) or placebo (N = 171) in patients with
mCRPC with asymptomatic or minimally symptomatic
disease, and an expected survival of at least 6 months
[42]. Prior to enrollment in the phase 3 sipuleucel-T
trial, patients had to be post-chemotherapy for longer
than 3 months and not have visceral metastases; in addi-
tion, these patients were required to be asymptomatic or
minimally symptomatic. Sipuleucel-T treatment reduced
the relative risk of death by 22% (HR = 0.78; 95% CI =
0.61-0.98; P = 0.03) and increased median survival by
4.1 months (25.8 vs 21.7). Despite the observation of
survival extension, however, no effects were seen on
either tumor response or time to tumor progression.
The treatment was well tolerated with predominantly
grade 1 and 2 infusion-related AEs such as fever and
chills [42]. The findings of IMPACT demonstrated the
first significant survival benefit for an immunotherapy in
patients with CRPC. It should be noted, however, that
the trial involved mostly patients who were docetaxel-
naïve (≥85%), so the utility of this treatment in the post-
docetaxel space requires further study [42].
In addition to sipuleucel-T, various other vaccination
approaches are under development in prostate cancer.
In a randomized phase 2 trial, PROSTVAC-VF demon-
strated an improvement in survival without effects on
disease progression in patients with asymptomatic or
minimally symptomatic metastatic CRPC [43]. This
agent uses a PSA antigen presented in the context of 3
co-stimulatory molecules (ICAM-1, BLA-7, and LFA-3)
which, when taken together, demonstrate an increase in
strength of the targeted immunologic response. A phase
3, 1,200-patient trial with PROSTVAC-VF is planned in
the near term future. Other novel vaccine approaches
under current development include transdermally admi-
nistered dendritic cells pulsed with PSMA peptides and
transduced with a modified CD40 which can be acti-
vated in vivo with chemically defined chemical moiety
[44]. These modifications permit prolonged activation of
CD40-expressing dendritic cells.
Endothelin receptor antagonism
As noted earlier, activation of other signaling pathways
m a yp l a yar o l ei nt h ee m e r g e n c eo fC R P C .T h ei n t e r a c -
tion of endothelin-1 (ET-1) with the G-protein coupled
endothelin-A (ETA) receptor has been implicated in car-
cinogenesis, and results in the triggering of several intra-
cellular signaling pathways [45]. ET-1 and the ETA
receptor may be involved in a number of processes in
CRPC, including cell growth and survival, angiogenesis,
development of bone metastases, and the nociceptive
response [45,46]. ZD4054 is a potent, orally available
endothelin receptor antagonist that has a high selectivity
for the ETA receptor [45]. In phase 2 studies, ZD4054
improved survival significantly for men with CRPC and
bone metastases (HR = 0.55; 95% CI = 0.41-0.73; P =
0.008) [47]. Placebo-controlled, phase 3 clinical trials
were planned for ZD4054; however, interim analyses
have failed to demonstrate a significant benefit on survi-
val for patients with mCRPC [48]. Recent results also
indicate that non-metastatic CRPC patients fail to bene-
fit. Final results of the trial with docetaxel/prednisone are
pending [23]. Atrasentan is another antagonist of ETA
that has been evaluated in two placebo-controlled phase
3 studies of men with CRPC [24]. Thus far, significant
effects on disease progression and survival have not been
observed with this agent, but SWOG has an ongoing
phase 3 trial that has completed accrual in combination
with docetaxel/prednisone [24].
Selection of therapy for CRPC
With the range of newer treatment options becoming
available, it is clear there will be a need to more carefully
define the most appropriate treatment for individual
patients with CRPC. As the incidence of prostate cancer
is disproportionately high in elderly men, consideration
should be given to life expectancy issues, functional sta-
tus, and the ability of a patient to tolerate potential side
effects of therapies [49]. Because elderly patients also
may benefit from chemotherapies to the same degree
that younger patients do, we should ensure that all treat-
ment options that prolong survival, control symptoms,
reduce pain, and improve quality of life are available to
those patients with good clinical status[49]. Strategies
such as proteomic profiling have been used to define
markers that predict docetaxel resistance in men with
mCRPC, and use of such biomarkers potentially could
better define which patients will experience recurrence
early on docetaxel therapy and direct these patients to a
more appropriate therapy [50]. Other surrogate biomar-
kers for prediction of clinical benefit in mCRPC include
PSA, bone turnover markers, bone pain, bone scans, and
circulating tumor cells [51]. The use of these surrogate
biomarkers has the potential to improve patient selection
strategies, and more rapidly identify agents that merit
further testing in phase 3 clinical trials, as well as acceler-
ate phase 3 testing. However, these markers will require
validation for use in patients with mCRPC [51].
Conclusions and future prospects
While initial responses to hormone-based therapies for
prostate cancer are favorable, patients ultimately will
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hormonal manipulation. Previous therapies for CRPC
were of a palliative nature, and no proven survival benefit
for a CRPC treatment was established until 2004, when
docetaxel was proven to prolong survival. The use of a
docetaxel-based regimen as first-line chemotherapy is
now considered a standard of care for men with mCRPC.
It is now clear that other treatment modalities, including
immunotherapy with sipuleucel-T, are effective options
for patients with asymptomatic or minimally sympto-
matic mCRPC. Patients in the “post-docetaxel space”
have presented the greatest challenge for ongoing
research over the past several years. Thus far, two agents
have shown considerable activity in this setting, including
cabazitaxel and AA (Table 1). The critical endpoint in
the “post-docetaxel” space has been extending OS; the
results of recent phase 3 trials with OS as a primary end-
point have been encouraging (Table 1). In view of the
persistence of androgen signaling in mCRPC, results
from additional ongoing phase 3 studies, particularly
with novel therapies targeted at the AR (e.g., MDV3100),
also are awaited with interest. In addition, patient selec-
tion for the particular type of therapy will be all-impor-
tant, and further research is necessary to define patient
characteristics and subgroups most able to benefit from
each of these emergent therapies. The future will likely
bring a number of possibilities for combination therapy,
sequential therapy, and other treatment modalities
advantageous to certain subgroups within the difficult-
to-treat population of patients with mCRPC.
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